Your browser doesn't support javascript.
loading
Factors associated with quality of life and functional disability among rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs for at least 6 months.
Bae, Sang-Cheol; Cho, Soo-Kyung; Won, Soyoung; Lee, Hye-Soon; Lee, Sang-Heon; Kang, Young Mo; Lee, Sang-Hoon; Lee, Yeon-Ah; Choe, Jung-Yoon; Chung, Won-Tae; Suh, Chang-Hee; Shim, Seung-Cheol; Lee, Jisoo; Yoon, Bo Young; Kim, Dong-Wook; Lee, Shin-Seok; Yoo, Wan-Hee; Kim, Jin-Seok; Jung, Young-Ok; Nah, Seong-Su; Lee, Choong-Ki; Song, Gwan-Gyu; Choi, Sung Jae; Joung, Chung-Il; Koh, Hyein; Kim, Young-Joo.
Afiliação
  • Bae SC; Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea.
  • Cho SK; Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea.
  • Won S; Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea.
  • Lee HS; Hanyang University Guri Hospital, Guri, South Korea.
  • Lee SH; Konkuk University Medical Center, Seoul, South Korea.
  • Kang YM; Kyungpook National University Hospital, Daegu, South Korea.
  • Lee SH; Kyung Hee University Hospital at Gangdong, Seoul, South Korea.
  • Lee YA; School of Medicine, Kyung Hee University, Seoul, South Korea.
  • Choe JY; School of Medicine, Catholic University of Daegu, Daegu, South Korea.
  • Chung WT; Department of Internal Medicine, Dong-A University Hospital, Busan, South Korea.
  • Suh CH; Ajou University Hospital, Suwon, South Korea.
  • Shim SC; Chungnam National University Hospital, Daejeon, South Korea.
  • Lee J; Ewha Womans University Mokdong Hospital, Seoul, South Korea.
  • Yoon BY; Inje University Ilsan Paik Hospital, Goyang, South Korea.
  • Kim DW; Inje University Pusan Paik Hospital, Busan, South Korea.
  • Lee SS; Chonnam National University Hospital, Gwangju, South Korea.
  • Yoo WH; Chonbuk National University Hospital, Jeonju, South Korea.
  • Kim JS; School of Medicine, Jeju National University, Jeju, South Korea.
  • Jung YO; Hallym University, Kang-Nam Sacred Heart Hospital, Seoul, South Korea.
  • Nah SS; Soonchunhyang University Hospital Cheonan, Cheonan, South Korea.
  • Lee CK; Yeongnam University Hospital, Daegu, South Korea.
  • Song GG; Korea University Guro Hospital, Seoul, South Korea.
  • Choi SJ; Korea University Ansan Hospital, Ansan, South Korea.
  • Joung CI; Konyang University Hospital, Daejeon, South Korea.
  • Koh H; Outcomes Research/Real World Data Team Corporate Affairs and Health & Value Division, Pfizer Pharmaceuticals Korea Limited, Seoul, South Korea.
  • Kim YJ; Outcomes Research/Real World Data Team Corporate Affairs and Health & Value Division, Pfizer Pharmaceuticals Korea Limited, Seoul, South Korea.
Int J Rheum Dis ; 21(5): 1001-1009, 2018 May.
Article em En | MEDLINE | ID: mdl-29878615
AIM: To determine characteristics of rheumatoid arthritis (RA) patients in Korea using disease-modifying anti-rheumatic drugs (DMARDs) for at least 6 months, and to identify factors associated with poor health-related outcomes. METHOD: A total of 2000 RA patients aged > 20 years, treated with DMARDs for at least 6 months, and signed informed consent, were enrolled in this non-interventional, multicenter, cross-sectional observational study from December 2012 to June 2013. Health-related quality of life (HRQoL) was measured using EuroQuol 5D (EQ-5D) and functional disability was measured using the Korean Health Assessment Questionnaire (KHAQ). Univariate and multivariate linear regression analyses were used to determine the association between patient characteristics and patient-reported outcomes (PROs). RESULTS: Of all RA patients, 84% were female, patients with low Disease Activity Score of 28 joints erythrocyte sedimentation rate (DAS-28-ESR < 3.2) was 54%, while moderate (DAS-28-ESR 3.2-5.1) and high disease activity score (DAS-28-ESR > 5.1) were 38% and 7.6%, respectively. Mean EQ-5D index score and KHAQ score were 0.6 ± 0.28 and 0.7 ± 0.67, respectively. In multivariate analysis with both PROs, average HRQoL and functional disability score appeared to be worse in persons with older age compared to younger age (P < 0.001), and worse in females compared to males (P < 0.001). Compared to patients having lower DAS (< 3.2), those with moderate and highest DAS (3.2-5.1 and > 5.1) had worse outcome measures (P < 0.001). CONCLUSION: In this study, higher DAS was one of the most influential factors for poor PROs among all other factors. Therefore, we could suggest appropriate treatment approaches according to DAS along with other significantly associated factors with PROs in the early stage of RA.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Artrite Reumatoide / Qualidade de Vida / Antirreumáticos / Avaliação da Deficiência Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: Int J Rheum Dis Assunto da revista: REUMATOLOGIA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Coréia do Sul

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Artrite Reumatoide / Qualidade de Vida / Antirreumáticos / Avaliação da Deficiência Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: Int J Rheum Dis Assunto da revista: REUMATOLOGIA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Coréia do Sul